These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 23549019)

  • 1. Gefitinib in non-small cell lung carcinoma: a case report of an unusual side effect and complete response in advanced disease.
    Laterza MM; Chiurazzi B; Brangi M; Riccardi F; Cartenì G
    Tumori; 2013; 99(1):3e-5e. PubMed ID: 23549019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma MIP-1beta levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib.
    Kimura H; Kasahara K; Sekijima M; Tamura T; Nishio K
    Lung Cancer; 2005 Dec; 50(3):393-9. PubMed ID: 16153743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary TKI resistance in advanced non-small cell lung cancer with EGFR mutation: an open question.
    Giuliani J; Martelli S; Remo A; Bonetti A
    Tumori; 2015 Jul; 101(4):e115-7. PubMed ID: 25953440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR mutations in patients with non small-cell lung cancer in Bulgaria and treatment with gefitinib.
    Damyanov D; Koynov K; Naseva E; Bichev S
    J BUON; 2015; 20(1):136-41. PubMed ID: 25778308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.
    Yamaguchi H; Soda H; Nakamura Y; Takasu M; Tomonaga N; Nakano H; Doi S; Nakatomi K; Nagashima S; Takatani H; Fukuda M; Hayashi T; Tsukamoto K; Kohno S
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):331-8. PubMed ID: 20401612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of gefitinib during pregnancy: case report and literature review.
    Gil S; Goetgheluck J; Paci A; Broutin S; Friard S; Couderc LJ; Ayoubi JM; Picone O; Tcherakian C
    Lung Cancer; 2014 Sep; 85(3):481-4. PubMed ID: 24997732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations.
    Kuwako T; Imai H; Masuda T; Miura Y; Seki K; Yoshino R; Kaira K; Utsugi M; Shimizu K; Sunaga N; Tomizawa Y; Ishihara S; Ishizuka T; Mogi A; Hisada T; Minato K; Takise A; Saito R; Yamada M
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):761-9. PubMed ID: 26254024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
    Horiike A; Yamamoto N; Tanaka H; Yanagitani N; Kudo K; Ohyanagi F; Ono A; Naito T; Murakami H; Horai T; Nishio M
    Anticancer Res; 2014 Apr; 34(4):1975-81. PubMed ID: 24692734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study.
    Ramalingam S; Forster J; Naret C; Evans T; Sulecki M; Lu H; Teegarden P; Weber MR; Belani CP
    J Thorac Oncol; 2008 Mar; 3(3):258-64. PubMed ID: 18317068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer.
    Yoshida K; Yatabe Y; Park JY; Shimizu J; Horio Y; Matsuo K; Kosaka T; Mitsudomi T; Hida T
    J Thorac Oncol; 2007 Jan; 2(1):22-8. PubMed ID: 17410005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First Reported Case of Unexpected Response to an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the I744M Uncommon EGFR Mutation.
    Kempf E; Lacroix L; Soria JC
    Clin Lung Cancer; 2015 Nov; 16(6):e259-61. PubMed ID: 26206728
    [No Abstract]   [Full Text] [Related]  

  • 13. A retrospective analysis of 335 Japanese lung cancer patients who responded to initial gefitinib treatment.
    Nishino K; Imamura F; Morita S; Mori M; Komuta K; Kijima T; Namba Y; Kumagai T; Yamamoto S; Tachibana I; Nakazawa Y; Uchida J; Minami S; Takahashi R; Yano Y; Okuyama T; Kumanogoh A
    Lung Cancer; 2013 Nov; 82(2):299-304. PubMed ID: 24018023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
    Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations.
    Sugiyama E; Umemura S; Nomura S; Kirita K; Matsumoto S; Yoh K; Niho S; Ohmatsu H; Tsuboi M; Ohe Y; Goto K
    Lung Cancer; 2015 Nov; 90(2):307-13. PubMed ID: 26323212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.
    Yang XB; Wu WY; Long SQ; Deng H; Pan ZQ; He WF; Zhou YS; Liao GY; Li QP; Xiao SJ; Cai JZ
    Trials; 2015 Apr; 16():146. PubMed ID: 25873045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity.
    Yonesaka K; Suzumura T; Tsukuda H; Hasegawa Y; Ozaki T; Sugiura T; Fukuoka M
    Anticancer Res; 2014 Sep; 34(9):5211-5. PubMed ID: 25202117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting sensitivity of non-small-cell lung cancer to gefitinib: is there a role for P-Akt?
    Pao W; Miller VA; Venkatraman E; Kris MG
    J Natl Cancer Inst; 2004 Aug; 96(15):1117-9. PubMed ID: 15292378
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety of gefitinib in non-small cell lung cancer treatment.
    Hsiue EH; Lee JH; Lin CC; Yang JC
    Expert Opin Drug Saf; 2016 Jul; 15(7):993-1000. PubMed ID: 27212579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib.
    Jackman DM; Holmes AJ; Lindeman N; Wen PY; Kesari S; Borras AM; Bailey C; de Jong F; Jänne PA; Johnson BE
    J Clin Oncol; 2006 Sep; 24(27):4517-20. PubMed ID: 16983123
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.